Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation. (NeutroCure)
Third Party Funds Group - Sub project
Acronym:
NeutroCure
Start date :
01.01.2020
End date :
31.12.2024
Overall project details
Overall project
Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation.
